|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/519 | |
| A61P 35/00 | |||
| A61K 31/18 | |||
| A61K 31/277 | |||
| A61K 31/52 |
| (11) | Number of the document | 2983669 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14715293.8 |
| Date of filing the European patent application | 2014-04-04 | |
| (97) | Date of publication of the European application | 2016-02-17 |
| (45) | Date of publication and mention of the grant of the patent | 2018-10-24 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2014/056768 |
| Date | 2014-04-04 |
| (87) | Number | WO 2014/166820 |
| Date | 2014-10-16 |
| (30) | Number | Date | Country code |
| 13162710 | 2013-04-08 | EP | |
| 13184240 | 2013-09-13 | EP |
| (72) |
LIU, Ningshu, DE
HAIKE, Katja, DE
PAUL, Juliane, DE
WENGNER, Antje Margret, DE
|
| (73) |
Bayer Pharma Aktiengesellschaft,
Müllerstrasse 178, 13353 Berlin,
DE
|
| (54) | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR TREATING LYMPHOMAS |
| USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR TREATING LYMPHOMAS |